Owlet’s First Baby Sleep Report Analyzes Data from Over 1.2 Million Owlet Monitored Babies

Key Terms

fda-cleared regulatory

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

biometric medical

Biometric describes measurements of unique physical or behavioral traits—like fingerprints, face shape, voice, or the way someone types—used to identify or verify a person. For investors, biometrics matter because they underpin products and services that promise stronger security or convenience, create new market opportunities, and raise regulatory and privacy risks that can affect a company’s costs, customer trust, and long-term value.

pulse rate medical

Pulse rate is the number of times the heart beats per minute, typically measured at the wrist or neck, and reflects how hard the body is working to circulate blood. Investors watch pulse rate because sustained increases or decreases can signal patient responses or side effects in clinical trials, influence regulatory assessments, and affect demand for treatments and health devices. Think of it like an engine’s RPMs: changes can indicate normal activity or a potential problem that matters to outcomes and forecasts.

Report draws on Owlet’s massive infant sleep dataset, one of the world’s largest, to reveal how babies sleep – evaluating bedtimes, wake-ups, sleep stretches, and biometric trends

LEHI, Utah--(BUSINESS WIRE)-- Owlet, Inc. (“Owlet” or the “Company”) (NYSE: OWLT), the pioneer of smart infant monitoring, today released its first annual Baby Sleep Report, a review of sleep data gathered from over the 1.2 million babies monitored by Owlet products in 2025. The global report analyzes nearly 900 million hours of monitored infant sleep from babies across 200 geographic regions, offering new insight into sleep patterns, trends, and development – providing parents with data-informed insights to common sleep concerns, while also helping them better understand the connection between sleep and overall wellness.

According to the CDC, approximately 40% of infants aged 4-11 months experience short sleep duration, with insufficient sleep linked to poor physical and mental health, attention and behavior problems, and poor cognitive development. Approximately one-quarter to one-half of all parents perceive their child's sleep as problematic, yet they often lack a clear understanding of what a typical sleep pattern looks like or how to make changes over time.

In this report, Owlet offers clarity on what parents need to understand about their baby’s sleep by analyzing trends from babies using the Company’s smart infant monitors. Among them is Dream Sock^®, the only FDA-cleared smart baby wearable monitor on the market. By helping families interpret sleep patterns over time and identify meaningful trends, Owlet brings the level of insight and context to infant sleep that consumers have come to expect from adult health wearables. With real-life data on infant sleep duration and patterns, night wakings by age, sleep consolidation milestones, and biometric trends, the report helps parents understand baby sleep development stages, recognize sleep progress, and feel more confident about their infant's sleep habits.

Key findings from Owlet’s 2025 Baby Sleep Report include:

• 80% of bedtime changes happen in the first six months: Baby sleep stabilizes faster than most parents expect, with both bedtime and morning wake times largely settling by mid–first year.
• By 6–8 months, babies on average sleep nearly nine hours at a time: Median longest nighttime sleep stretches grow from about 4 hours in early infancy to nearly 9 hours by 6–8 months, even though some night wakings may continue.
• Night wakings drop by more than half by 9 months: By around 9 months, most babies experience significantly fewer night wakings, marking a major turning point for families.
• Biggest sleep and pulse rate changes happen in the first two months: Across millions of nights, the most dramatic changes in sleep patterns and pulse rate occur between the first and second months, before gradually slowing over time.
• Early high pulse rates are common and usually reflect age-typical patterns: For most, elevated pulse rates in younger babies fall within expected ranges, and these patterns begin to level out by around six months as sleep becomes more consistent, suggesting that more consistent physiological patterns emerge well before toddlerhood.
• Pulse rate remains higher during light sleep than deep sleep: Pulse rate is higher during light sleep, when the brain is more active and babies are more likely to move or wake. Deep sleep is generally more restorative, with lower pulse rates and fewer disruptions. As babies grow and spend less time in light sleep, both sleep and pulse rate patterns naturally become more stable.

“Our first-ever Baby Sleep Report reinforces Owlet’s leadership in data-driven infant sleep and wellness,” said Jonathan Harris, President and CEO of Owlet. “By leveraging insights from more than 1.2 million babies monitored last year alone, we provide parents with reassurance, context, and clearer insights, transforming nights into clarity and peace of mind. We are helping families interpret sleep patterns over time and recognize meaningful changes to better support more informed pediatric conversations and greater awareness of how sleep fits into overall wellness.”

The insights revealed in this report are supported through the Dream App experience, including enhanced features available with an Owlet360™ membership (available in the U.S. and select international markets), which gives parents access to deeper trends and analytics to help them make sense of nightly patterns over time.

The full Annual Baby Sleep Report is available at www.babysleepreport.owletcare.com. For more information on Owlet and its ecosystem of smart monitoring products, including Dream Sock^®, Dream Duo^™, and Dream Sight^™, please visit www.owletcare.com.

The insights in this report are based on aggregated Owlet monitoring data from babies with active monitoring sessions during calendar year 2025, collected from users of Dream Sock and Smart Sock products in multiple countries where Owlet products are used. These insights describe patterns observed in Owlet users and may not represent all babies. Individual sleep patterns vary.

About Owlet, Inc.

Owlet, Inc. (NYSE: OWLT), a leading pediatric health platform, is the only company in the world to offer U.S. FDA-cleared and internationally medically-certified wearable pediatric monitors, delivering hospital-grade technology directly in the home. Our award-winning pediatric products and innovative software combine clinically tested monitoring systems, an integrated video platform, and a simple, easy-to-use app, providing parents with real-time health insights to stay informed on their child’s well-being, support restful sleep, and provide peace of mind anywhere. Since 2012, more than 2.5 million parents have trusted Owlet to monitor their children's well-being and sleep. This adoption has fueled one of the largest collections of pediatric health and sleep data in the world, powering innovations that bridge the critical gap between hospital and home. Owlet is driving a new standard in pediatric wellness by pairing advanced medical technology with consumer-friendly design. Our mission is simple yet ambitious: to give every baby and every family the best possible start in life. Learn more at www.owletcare.com and follow us on LinkedIn and Instagram for company news and updates.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Reform Act”). All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements regarding the Company’s first annual Baby Sleep Report and the anticipated benefits, insights, and impacts thereof; the Company’s expectations regarding how parents and other stakeholders may use or perceive the report’s insights; the Company’s ability to support and enhance its data analytics capabilities and related product experiences, including features available through an Owlet360™ subscription membership; the Company’s ability to expand availability of its products and services in additional markets; and the Company’s ability to enhance its technology, product ecosystem, and service offerings over time. In some cases, you can identify forward-looking statements by terms such as “estimate,” “may,” “believes,” “plans,” “expects,” “anticipates,” “intends,” “goal,” “potential,” “continues,” the negation thereof, or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are based on the Company’s expectations at the time such statements are made, speak only as of the dates they are made, and are susceptible to a number of risks, uncertainties, and other factors. For all such forward-looking statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Reform Act. The Company’s actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by its forward-looking statements. Many important factors could affect the Company’s future results and cause those results to differ materially from those expressed in or implied by the Company’s forward-looking statements. Such factors include, but are not limited to: (i) the commercial success of Owlet’s products, including the Company’s subscription services and data-driven product features and the Company’s ability to support, scale and maintain its subscription services; (ii) the regulatory pathway for Owlet’s products, including submissions to, actions taken by and decisions and responses from regulators, such as the FDA and similar regulators outside of the United States, as well as Owlet’s ability to obtain and maintain regulatory approval or certification for its products and comply with ongoing regulatory requirements; (iii) the Company’s and its partners’ obligations relating to data privacy, security and the exchange and use of health information, and risks of cybersecurity incidents or changes in applicable standards or interpretations; (iv) the performance of, and Owlet’s ability to maintain and expand, its relationship with third-party technology, cloud, manufacturing and distribution partners; (v) Owlet’s competition and the Company’s ability to profitably grow and manage growth; (vi) the ability of Owlet to implement strategic initiatives, reduce costs, grow revenues, develop and launch new products, innovate and enhance existing products, meet customer demands and adapt to changes in consumer preferences and retail trends; (vii) Owlet’s ability to acquire, defend and protect its intellectual property and satisfy regulatory requirements concerning privacy and data protection; (viii) Owlet’s ability to maintain relationships with channel partners, customers, manufacturers and suppliers; (ix) impacts from compliance with applicable laws or regulations; (x) the impact of and disruption to Owlet’s business, financial condition, operations, supply chain and logistics due to economic and other conditions beyond the Company’s control; (xi) adverse impacts from other economic, business, regulatory, competitive or other factors, such as changes in discretionary consumer spending and consumer preferences; and (xii) other risks and uncertainties set forth in the Company’s other releases, public statements and filings with the U.S. Securities and Exchange Commission (“SEC”), including those identified in the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, and as any such factors may be updated from time to time in the Company’s other filings with the SEC. All such forward-looking statements attributable to the Company or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to above. Moreover, the Company operates in an evolving environment. New risk factors and uncertainties may emerge from time to time, and factors that the Company currently deems immaterial may become material, and it is impossible for the Company to predict such events or how they may affect Owlet. Except as required by law, the Company assumes no obligation to update any forward-looking statements after the date of this press release, whether because of new information, future events or otherwise, although Owlet may do so from time to time. The Company does not endorse any projections regarding future performance that may be made by third parties.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260121228785/en/

Media Contact:

pr@owletcare.com

Investor Contact:

ir@owletcare.com

Source: Owlet, Inc.